| Sign In | Join Free | My futurenowinc.com |
|
| Sign In | Join Free | My futurenowinc.com |
|
| Categories | Plant Extract Oligosaccharides |
|---|---|
| Brand Name: | NUGLY |
| Model Number: | CGO/CK |
| Certification: | FDA,ISO9001,ISO22000,FSSC22000 |
| Place of Origin: | China |
| MOQ: | 1mg |
| Price: | FOB Shanghai USD27.9/mg |
| Payment Terms: | T/T,PAYPAL |
| Supply Ability: | 1ton/year |
| Delivery Time: | 10-20 work days |
| Packaging Details: | 1mg/bottle，10mg/bottle |
| Product: | Rare Ginsenoside Ck Ginsenoside Compound K |
| Functions: | Anti inflammatory agents for treating inflammatory bowel disease |
| Usage Method: | Drug formula, health product formula |
| Suitable People: | Tumor patients、Sub healthy population |
| Color: | White |
| Grade: | Medical Grade |
| Storage: | Dry and Shade |
| Water Solubility: | Water Soluble |
| Shelf Life: | 24 Months |
| CAS No.: | 39262-14-1 |
| Specification: | Purity More Than 80% |
| Molecular Weight: | 622.873 |
| Source: | Ginseng extract, Total Saponins of Ginseng |
| Molecular Formula: | C36H62O8 |
| Density: | 1.05-1.1 |
High Purity Rare Ginsenoside Ck Ginsenoside Compound K
【Biological activity】
Ginsenoside C-K is a bacterial metabolite of Ginsenoside Rb1.
Ginsenoside C-K exerts anti-inflammatory effects by inhibiting
inducible nitric oxide synthase (iNOS) and COX-2.
In human liver microsomes, Ginsenoside C-K inhibits CYP2C9 and
CYP2A6 activity with IC50 values of 32.0 ± 3.6 μ M and 63.6 ± 4.2 μ
M, respectively.
【Product Specifications Of Rare Ginsenoside Ck Ginsenoside Compound K】
| Appearance | White powder |
| Other Name | Medical grade Compound K |
| Applicable objects | Tumor patients |
| Product form | Powder |
| Purity | 80% |
| Deacetylation degree | >90% |
| Viscosity (5%) | <10cps |
| Molecular weight | Around 600DA |
| loss on drying | <10% |
| residue on ignition | <1% |
| insoluble | <1% |
| pb | <2ppm |
| As | <1ppm |
| total plate count | <1000 cfu/g |
| mole and yeast | <25 cfu/g |
| E. coli | Negative |
| particle size | >80 mesh |
【In vitro research Of High Purity Rare Ginsenoside Ck Ginsenoside Compound K】
Ginsenoside CK, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX), and pro-inflammatory cytokines.
Ginsenoside CK inhibits the expression of pro-inflammatory
cytokines by downregulating the activities of IRAK-1, MAPK, IKK -
α, and NF - κ B in LPS treated mouse peritoneal macrophages.
Ginsenoside CK also inhibits the expression of iNOS and COX-2 by
suppressing NF - κ B signaling in RAW264.7 cells stimulated by LPS.
In bone marrow-derived macrophages (BMDM) and RAW264.7 cells
treated with yeast polysaccharides, ginsenoside CK inhibits
inflammatory responses by negatively regulating the secretion of
pro-inflammatory cytokines, activation of MAPK, and production of
ROS. In addition, anti-inflammatory activity of ginsenoside CK was
observed in LPS stimulated microglia.
Ginsenoside CK inhibits inflammatory responses by controlling the
production of ROS and the activity of MAPKs, NF - κ B, and AP-1.
Ginsenoside CK is the main metabolite of ginsenosides in the gastrointestinal tract, which inhibits NF - κ B signaling in a PXR dependent manner.
Ginsenoside CK promotes the recovery of colitis induced by dextran sulfate sodium (DSS) by inhibiting NF - κ B activation. Ginsenoside CK significantly reduced the upregulation of IL-1 β and iNOS mRNA levels induced by TNF - α, and restored the mRNA levels of PXR and CYP3A4 in LS174T cells.
Ginsenoside CK is one of the intestinal metabolites of 20 (S) -
protopanaxadiol derivatives, which has an inhibitory effect on the
activity of CYP2C9 in human liver microsomes with an IC50 value of
32.0 ± 3.6 μ M. The inhibitory effect on CYP2A6 activity in human
liver microsomes is weaker with an IC50 value of 63.6 ± 4.2 μ M,
and the inhibitory effect on CYP2D6 activity in human liver
microsomes is weaker with an IC50 value exceeding 100 μ M
|
